These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 30857817)
1. Commentary: 2B or 2A, that is the question. Hui DS; Lee R J Thorac Cardiovasc Surg; 2022 Jul; 164(1):e33. PubMed ID: 30857817 [No Abstract] [Full Text] [Related]
2. Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question'. Toyoda H; Kumada T Expert Opin Pharmacother; 2009 Dec; 10(17):2845-57. PubMed ID: 19891593 [TBL] [Abstract][Full Text] [Related]
4. Peginterferon alfa-2b vs. peginterferon alfa-2a in the treatment of hepatitis C, is there any difference? Sierra F J Hepatol; 2007 Feb; 46(2):349; author reply 349-50. PubMed ID: 17161495 [No Abstract] [Full Text] [Related]
5. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). Silva M; Poo J; Wagner F; Jackson M; Cutler D; Grace M; Bordens R; Cullen C; Harvey J; Laughlin M J Hepatol; 2006 Aug; 45(2):204-13. PubMed ID: 16780997 [TBL] [Abstract][Full Text] [Related]
6. Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients. Miyase S; Haraoka K; Ouchida Y; Morishita Y; Fujiyama S J Gastroenterol; 2012 Sep; 47(9):1014-21. PubMed ID: 22382633 [TBL] [Abstract][Full Text] [Related]
7. Proceed with caution: peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials. Kershenobich D; Muñoz L; Malé R; Gaytan J; Sánchez F Hepatology; 2010 Dec; 52(6):2240-1; author reply 2241-2. PubMed ID: 21105116 [No Abstract] [Full Text] [Related]
8. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials. Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315 [TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain. Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866 [TBL] [Abstract][Full Text] [Related]
11. Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis. Yokoyama S; Kawakami Y; Imamura M; Hayes CN; Kohno H; Kohno H; Tsuji K; Aisaka Y; Kira S; Yamashina K; Nonaka M; Takahashi S; Moriya T; Kitamoto M; Aimitsu S; Nakanishi T; Kawakami H; Chayama K J Gastroenterol Hepatol; 2015 Feb; 30(2):337-44. PubMed ID: 25091289 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China. Hu Y; Ye YZ; Ye LJ; Wang XH; Yu H World J Pediatr; 2019 Dec; 15(6):595-600. PubMed ID: 31487005 [TBL] [Abstract][Full Text] [Related]
13. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Foster GR Drugs; 2010; 70(2):147-65. PubMed ID: 20108989 [TBL] [Abstract][Full Text] [Related]
14. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients. Dogan UB; Golge N; Akin MS Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913 [TBL] [Abstract][Full Text] [Related]
15. Comment on a systematic review of randomized trials of peginterferon alpha-2a versus peginterferon alpha-2b in chronic hepatitis C. Singal AK; Jampana SC; Anand BS Hepatology; 2011 Jun; 53(6):2151. PubMed ID: 21538429 [No Abstract] [Full Text] [Related]
16. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Singal AK; Jampana SC; Anand BS Dig Dis Sci; 2011 Aug; 56(8):2221-6. PubMed ID: 21643737 [TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875 [TBL] [Abstract][Full Text] [Related]
18. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224 [TBL] [Abstract][Full Text] [Related]
19. The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation. Hartwell D; Cooper K; Frampton GK; Baxter L; Loveman E Health Technol Assess; 2014 Oct; 18(65):i-xxii, 1-202. PubMed ID: 25350588 [TBL] [Abstract][Full Text] [Related]
20. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study. Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]